Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Urogen Pharma Ltd URGN

Healthcare Biotechnology
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of... see more

Current News (NDAQ:URGN)

UroGen Applauds BCAN's New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence

GlobeNewswire 3 days ago

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 9 days ago

UroGen Announces ZUSDURI(TM) Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results

GlobeNewswire March 2, 2026

UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors

GlobeNewswire March 2, 2026

ZUSDURI(TM) Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC

GlobeNewswire February 27, 2026

UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference

GlobeNewswire February 24, 2026

UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026

GlobeNewswire February 23, 2026

UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit

GlobeNewswire February 4, 2026

Permanent J Code for ZUSDURI(TM) Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy

GlobeNewswire January 5, 2026
View More News ››

Opinion & Analysis (NDAQ:URGN)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:URGN)

UroGen Pharma Ltd.: Positioning for Significant Growth with

http://beyondspx.com/2024/07/31/urogen-pharma-ltd-positioning-for-significant-growth-with-promising-pipeline-and-approved-product/
MikeTester - August 2, 2024
View more Bullboard ››

Cameo Resources Inc

Cameo Resources Inc

Cameo Resources Inc. engages in the acquisition, exploration, and development of mineral deposits. It primarily focuses on ...
View More »

Podcasts